Global Wealth Management Investment Advisory Inc. Sells 1,620 Shares of Amgen Inc. $AMGN

Global Wealth Management Investment Advisory Inc. decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 9.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,081 shares of the medical research company’s stock after selling 1,620 shares during the quarter. Global Wealth Management Investment Advisory Inc.’s holdings in Amgen were worth $6,357,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Wellington Altus USA Inc. increased its position in shares of Amgen by 72.3% during the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after buying an additional 34 shares during the period. Quest 10 Wealth Builders Inc. raised its stake in Amgen by 220.0% during the third quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock worth $34,000 after buying an additional 55 shares during the last quarter. Nvwm LLC raised its stake in Amgen by 412.5% during the third quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after buying an additional 66 shares during the last quarter. Security National Bank of Sioux City Iowa IA acquired a new position in Amgen in the second quarter valued at $36,000. Finally, PFS Partners LLC lifted its holdings in Amgen by 95.5% in the third quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock valued at $36,000 after buying an additional 42 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on AMGN. Morgan Stanley upped their price target on shares of Amgen from $359.00 to $410.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 4th. TD Cowen increased their price target on Amgen from $452.00 to $531.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Bank of America lifted their price objective on Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. Sanford C. Bernstein boosted their price objective on Amgen from $345.00 to $400.00 and gave the company a “market perform” rating in a research note on Wednesday, November 4th. Finally, Oppenheimer reissued an “outperform” rating on shares of Amgen in a research note on Friday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, Amgen has an average rating of “Hold” and a consensus price target of $422.76.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New AHA 2026 data reinforced Repatha’s potential: an analysis found it cost-effective for high-risk patients without a prior heart attack or stroke, while a separate long-term analysis associated treatment with a 29% lower risk of major cardiovascular events in patients with ASCVD. The findings could support wider use, though the reported analyses do not guarantee future sales growth. Article: New Repatha data at AHA 2026
• Positive Sentiment: Amgen is heading into ACR week with a dazodalibep update expected November 11, creating a near-term clinical catalyst for its pipeline. The article headline does not specify the results, so the update’s impact will depend on the data. Article: Amgen stock heads into ACR week with dazodalibep update
• Positive Sentiment: An article highlighted experimental obesity drug MariTide’s potential to reduce dosing from 52 injections a year to four. If borne out in clinical development, less frequent dosing could be a competitive advantage; the drug remains experimental. Article: Amgen’s new drug could mean fewer shots for obesity patients
• Neutral Sentiment: Amgen shares rose in Monday trading but underperformed the broader market, indicating the move was not as strong as the overall market’s. Article: Amgen stock rises Monday, still underperforms market
• Negative Sentiment: ETFs were net sellers of $68.5 million of AMGN on November 5, a potential near-term supply headwind, although 51 funds bought shares and 20 sold. Article: ETFs are net sellers of Amgen

Amgen Stock Performance

NASDAQ:AMGN opened at $465.23 on Tuesday. The company has a fifty day moving average of $423.08 and a 200-day moving average of $378.80. The firm has a market capitalization of $251.52 billion, a P/E ratio of 26.99, a P/E/G ratio of 3.47 and a beta of 0.43. The company has a quick ratio of 1.13, a current ratio of 1.48 and a debt-to-equity ratio of 3.60. Amgen Inc. has a twelve month low of $312.39 and a twelve month high of $483.99.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The company had revenue of $10.37 billion for the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. Amgen’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.64 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 23.33 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s payout ratio is 58.47%.

Amgen Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases.

The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally.

Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A.